Analysts Lift Targets as KYMR Options Turn Bullish Before Q3 Print

Kymera Therapeutics goes into its November 5 results with the stock up 11% in a single week, a wave of analyst target increases still landing, and options positioning that has turned noticeably more call-heavy, an unusual alignment for a clinical-stage biotech carrying 12.8% short interest.

The options shift is the sharpest near-term signal. The put/call ratio has dropped to 0.79, more than two standard deviations below its 20-day average of 0.82. That is the most call-dominated reading the ratio has reached in months, sitting near the 52-week low of 0.30, and it follows a week in which the stock outperformed every one of its closest peers. NRIX, CGON, VERA and PTGX each fell between 2% and 4% on the day; KYMR closed up 0.7%. The 11% weekly move compares to a median of roughly 0.6% across the same peer group, a divergence that suggests stock-specific conviction rather than a sector tide.

The analyst community has been similarly directional. Barclays raised its target to $170 on November 2, maintaining Overweight. Morgan Stanley lifted to $146 and Truist to $150 in the days prior. The mean price target now sits at roughly $144, below where the stock already trades at $127.51, and the RBC Capital analyst carries a Sector Perform with a $116 target, the one meaningful dissenting voice in a broadly bullish consensus. The bull case centres on KT-621 as a potential first-in-class oral STAT6 degrader, with a phase 2b atopic dermatitis readout expected by year-end 2026 and a $1.5 billion cash balance providing runway. Bears point to enrollment risk in hidradenitis suppurativa and atopic dermatitis trials, plus the gap between promising early data and phase 3 execution.

Short interest has eased but remains substantial. The position pulled back roughly 6.6% over the past week to 12.8% of the free float, continuing a trend that began in early October when short interest was close to 10.5 million shares. Borrowing costs are low at 0.51% and availability is loose at around 355%, meaning roughly three and a half shares are available to lend for every one currently borrowed. There is no meaningful squeeze setup in the lending market. Two activists remain on the SEC 13D register: Baker Bros. Advisors LP at 10.9% (as last disclosed in December 2025, up from 9.5%) and BVF Partners at 6.3% (filed June 2026, down from 8.5%). As with all 13D/G stakes, these are as-last-disclosed around the 5% threshold, and positions may have changed without a further filing.

ORTEX forecasts an 93% probability that Kymera will be added to the Russell 1000 and a 90% probability of deletion from the Russell 2000 at the December 2026 Semi-Annual Review, with the announcement date pencilled in for November 13. The estimated buying flow from Russell 1000 trackers is $398 million, equivalent to about 4.1 days of normal trading volume. The stock closed 9.6% above the entry price of $114.45 that decides the addition. Among 120 comparable Russell 1000 additions in ORTEX's history, the median move from announcement to effective date was negative 3.6%, and only 32% moved in the expected direction. That history is what it is, not a template for this event.

The November 5 print will therefore test whether Kymera's clinical narrative, specifically the KT-621 timeline and any update on IRAK4 program enrollment, can hold a stock that has already priced in a significant amount of good news, with the index mechanics adding an additional mechanical buyer waiting in the wings.